July 22, 2021

Synaffix Announces Deal with ProfoundBio Worth up to $246 Million Providing Access to Multiple Novel Linker-Payload Technologies

AMSTERDAM–(BUSINESS WIRE)–Synaffix B.V., a biotechnology company focused on commercializing its clinical-stage platform technology that enables antibody-drug conjugates (ADCs) with best-in-class therapeutic index, today announced the signature of a license and option agreement with ProfoundBio, an emerging oncology biotherapeutics company. The deal provides access to multiple novel linker-payload technologies developed by Synaffix and includes access to the GlycoConnectâ„¢ glycan conjugation an


Leave Comment


Your Name *
Your Email *
Your Website
Comment *